The possibility to use CCR5-Δ32 umbilical cord blood to cure HIV infection in patients in need of a hematopoietic transplant has been suggested. The less stringent HLA compatibility needed in this type of transplant facilitates the search of a suitable donor having the CCR5-Δ32 mutation. To achieve an inventory of CCR5-Δ32 cord blood units, the 20,236 best cell quality units of the Spanish Registry were genotyped. Furthermore, their CD34 + and total nucleated cells counts, blood type, gender, HLA and donor's geographical and ancestral origin were analyzed. The results showed 130 (0.64%) units homozygous for the deletion, 2,646 (13.08%) heterozygous and 17,460 (86.28%) did not present the mutation. Interestingly, a significant lower amount of CD34 + cells was found in the CCR5-Δ32 homozygous units. In addition, a significant association was found among donor's ancestral origin and the mutation, with a higher percentage of CCR5-Δ32 units with a European ancestry. In summary, identification of a relatively high number of CCR5-Δ32 units is feasible and will facilitate the development of clinical trials for HIV cure in patients requiring hematopoietic transplantation. Further studies are required to understand the significance of lower cell counts within the CCR5-Δ32 homozygous group and its clinical impact.
Introduction
Human immunodeficiency virus type 1 (HIV-1) needs the cellular receptor CD4 and a co-receptor, most commonly the chemokine receptor CCR5, to infect target cells in the immune system [1] . A homozygous 32-base pair deletion in the CCR5 gene, which results in the expression of a nonfunctional receptor, confers natural resistance to CCR5-tropic HIV-1 infection [2] . Unfortunately, the frequency of the CCR5-Δ32 variant is around 7.7% in Caucasian descendent [3] , and <1% of this population would carry a CCR5-Δ32/Δ32 genotype. In addition, the allelic frequency of this mutation is lower in other ethnic groups [4, 5] . Noteworthy, heterozygous genotype (CCR5-Δ32/WT) does not protect from HIV-1 infection [2] , but may lead to a slower progression to AIDS than the CCR5-WT/WT genotype [6] [7] [8] .
In 2009, Hütter and colleagues published the case of a patient with HIV infection and AML who underwent hematopoietic cell transplant (HCT) from a CCR5-Δ32/Δ32 unrelated donor [9] . The patient, who had a predominant CCR5-tropic HIV-1 phenotype, has not shown evidence of HIV-1 infection for up to 9 years after HCT. Highly active antiretroviral therapy was withdrawn the day before transplant, becoming to our knowledge the only patient cured of HIV infection [10] [11] [12] .
The low prevalence of the CCR5-Δ32/Δ32 genotype and stringent HLA-matching criteria will make it very difficult to identify suitable related or unrelated adult volunteer donors for HCT [11] . Nevertheless, the higher tolerance to Human Leukocyte Antigen (HLA) mismatch in umbilical cord blood transplantation (UCBT) and their immediate availability in umbilical cord blood inventories, may make it the ideal cell source in this setting [13] [14] [15] [16] . Petz and colleagues [15] calculated the probabilities to find an appropriate HLA-matched cord blood unit (CBU) for transplantation from an inventory of 300 CCR5-Δ32/Δ32 CBUs. In the Caucasian population, the probabilities to find a suitable CBU with a total nucleated cell count (TNC) of ≥1E + 07/kg were 82.1% for adults and 85.6% for paediatric patients.
Recently, Duarte and colleagues from our group reported a HIV-positive patient with diffuse large B-cell lymphoma who underwent a CCR5-Δ32/Δ32 UCBT. Although the patient died 3 months after UCBT from disease progression, HIV DNA was not detectable after transplant in isolated CD4 + T cells, which were resistant ex vivo to HIVinfection [17] . Another case of CCR5-Δ32/Δ32 UCBT was reported in a patient without HIV infection. Upon full CCR5-Δ32/Δ32 donor chimerism, the patient's peripheral blood mononuclear cells were shown resistant in vitro to HIV infection [15] . These observations strongly suggest that the use of CCR5-Δ32/Δ32 UCBT could be a suitable therapeutic alternative for HIV-positive patients who require a HCT [18] .
To extend the availability of this approach, an international work is required to type thousands of CBU available for clinical use. Some initiatives have already been published (i.e., StemCyte International Cord Blood Centre has more than 200 units CCR5-Δ32/Δ32 already identified, approximately 0.8% of all tested) [18] . The Spanish Bone Marrow Registry (REDMO) has a high quality and second largest CBUs inventory. In 2014, the Spanish Transplant Organization sponsored a project within the "Plan Nacional de Sangre de Cordón Umbilical", to determine the CCR5 genotype in high-quality CBUs. The main objective of this study was to obtain an inventory of CCR5-Δ32/Δ32 CBUs ready for UCBT and to explore their biological characteristics of interest. Our purpose is to facilitate the future development of clinical trials using these CBUs for UCBT in HIV patients.
Materials and methods

CBU selection for CCR5 genotyping
This is a retrospective study analysing anonymized data from cord blood donors available at REDMO until 2015 and their donated samples. The procedures used in this study followed ethical standards as approved by the Vall Hebron University Hospital Ethical Committee and were performed in accordance with the Helsinki Declaration.
According to "Plan Nacional de Sangre de Cordón Umbilical", developed in Spain in 2006, all donors signed an informed consent for CBU donation. The informed consent allows the storage of CBU in the authorized Spanish public Cord Blood Banks (CBBs) for their use in HCT protocols and biomedical research and to perform immunogenetic test for an optimal donor selection.
From the whole Spanish Registry, 20,236 high quality CBUs with a TNC count of ≥1E + 09 from six different CBBs (Andalucía, Galicia, Madrid, País Vasco, Programa Concordia BST and Valencia) were selected for CCR5 genotyping (Table S1 ). CBBs provided DNA samples of the required units to their reference laboratories.
Genotyping of CCR5-Δ32 mutation
Histocompatibility and Immunogenetics laboratories of Barcelona, Madrid and Málaga were assigned to perform CCR5 genotyping according to a defined distribution (Table S1 ). Two different in-house methods were used for genotyping of selected samples: first, based in real-time PCR and the other one in capillary electrophoresis.
Genotyping with real-time PCR
To determine the different CCR5 genotypes of the studied CBUs a genotyping analysis using a real-time on a LightCycler® 480 System (Roche Diagnostics, Basilea, Switzerland) was performed. For PCR reaction 1 µl of genomic DNA was used in a total volume of 10 µl. The components of the reaction mixture were 1X Taqman® Universal PCR Master Mix (Applied Biosystems, Foster City, CA, USA); 600 nM forward (AGG TCT TCA TTA CAC CTG CAG CT) and reverse (AGC AGC GGC AGG ACC AG) primers; and 300 nM Taqman® MGB probes (5′ 6-FAM™-TCC ATA CAT TAA AGA T-MGB 3′ and 5′ VIC® AGT ATC AAT TCT GGA AGA AT-MGB 3′) specific for CCR5-Δ32 and CCR5-WT alleles respectively. The amplification program spent 2 min at 50°C (1 cycle); 10 min at 95°C (1 cycle); 15 s at 95°C and 1 min at 60°C (40 cycles). The different genotypes were assigned according to the emitted fluorescence signals (FAM™, FAM™ + VIC® or VIC®) as CCR5-Δ32/Δ32, CCR5-Δ32/WT and CCR5-WT/WT, respectively. The results were analysed with LightCycler ® 480 System software 1.5 (Roche Diagnostics).
Capillary electrophoresis and fragment analysis
This second method was used to verify CCR5-Δ32/Δ32 and CCR5-Δ32/WT CBUs. First, DNA samples were amplified using fluorescent PCR in a 9 700 Gene Amp® PCR System or 2 720 Thermal Cycler (Applied Biosystems). One microlitre of genomic DNA was mixed in a total volume of 12 µL. PCR solution contained Platinum® Taq DNA Polymerase (Invitrogen, Carlsbad, CA, USA), 10 × PCR Rxn Buffer, 2.5 mM dNTP's, 50 mM MgCl 2, and forward (TTCATTACACCTGCAGCTCTC) and reverse (FAM™-CCTGTTAGAGCTACTGCA ATTAT) primers (50 ng/µL). The PCR program consisted of 3 min at 94°C (one cycle); 20 s at 94°C, 30 s at 58°C and 15 s at 72°C (34 cycles); and 60 min at 72°C (1 cycle). The length of the CCR5-Δ32 allele was 270-bp, whereas the CCR5-WT allele produced a 302-bp PCR product. After amplification, 0.5 µL of PCR products were mixed in a 1:10 dilution with 24 µL of Hi-Di™ Formamide (Applied Biosystems) and 0.7 µL of Gene Scan™-500 ROX™ Size Standard (Applied Biosystems) and denatured at 94°C for 5 min. The capillary electrophoresis was carried out in a 3130xlGenetic Analyzer (Applied Biosystems) and samples were analysed with GeneMapper software (Applied Biosystems).
CBU data collection
From the whole inventory, REDMO exported data of CCR5 genotyped CBUs and distributed to CBBs to study their cellular and immunogenetic characteristics according to CCR5 genotyping. Different variables of interest were selected to perform the study: TNC and CD34 + cell count, HLA typing, gender, blood type, ancestral origin (grouped in African, European and South American ancestries and others with a less represented origin) and place of CBUs collection within Spain and Andorra (Table S1 ). The HLA genes studied were HLA-A, HLA-B and HLA-DRB1 in a low resolution, which were the ones that are analysed for the compatibility in cord blood HCT.
In addition, assignation of the most probable HLA haplotypes to each CCR5-Δ32/Δ32 CBU was performed using the HaploStats Application (http://www.haplostats.org), based on HLA frequencies according ethnic groups provided by the National Marrow Donor Programme Bioinformatics group.
Statistical analysis
Variables of interest were defined as continuous (TNC and CD34+ cell count) and discrete (HLA typing, gender, blood type, ancestral origin and place of CBUs collection). Statistical analysis was carried out to know the association between CCR5-Δ32 mutation and CBUs cell quality. For that, TNC and CD34
+ cell count of CCR5-WT/WT (WT), CCR5-Δ32/WT (HT) and CCR5-Δ32/Δ32 (HM) CBUs were compared. These variables were log-transformed and, after confirming data meet the assumptions of the tests, parametrical test ANOVA was applied and Tuckey test was used when significant differences were found with ANOVA test, with the aim to determine which groups were significantly different. Furthermore, association between CCR5 genotyping and the different discrete variables of the CBUs was analysed using chi-square test. All statistical tests were conducted with the "R" software (R version 3.3.1 from the R Foundation for Statistical Computing).
Results
CCR5 genotyping frequencies
Among the 20,236 CBU genotyped, 130 units were HM, 2,646 HT and 17,460 WT, with the corresponding genotypic frequencies of 0.64, 13.08 and 86.28%. The calculated allele frequencies were 7.18% for the CCR5-Δ32 allele and 92.82% for the CCR5-WT allele. These frequencies were similar among the different regions of CBUs collection (P = 0.847).
Cell counts according to CCR5 genotypes
The 20,236 CBUs studied present a mean of 1.67E + 09 TNC (1.00E + 09 to 6.09E + 09; SD = 3.97E + 08) and 6.49E + 06 CD34 + cells (2.60E + 05 to 1.11E + 08; SD = 4.60E + 06). These values reflect the high quality of the units analysed. In addition, TNC and CD34 + cell counts for each CCR5 group were analysed (Fig. 1) . Mean TNC values were 1.67E + 09 (SD = 3.94E + 08), 1.68E + 09 (SD = 4.19E + 08) and 1.61E + 09 (SD = 3.27E + 08) for the WT, HT and HM, respectively. CD34 + cell counts mean was 6.49E + 06 (SD = 4.63E + 06), 6.53E + 06 (SD = 4.44E + 06) and 5.35E + 06 (SD = 3.09E + 06) for the WT, HT and HM groups. Statistical significant differences were found in TNC value and CD34 + cells among the three CCR5 groups (P = 0.039 and P = 0.011 respectively), with a lower number of cells in CBUs that were homozygous for the CCR5-Δ32 deletion. Statistical significant differences in the CD34 + cells analysis after performing a multiple comparison test were found among HM and HT groups (P = 0.008) and also among HM and WT groups (P = 0.009).
CBUs characteristics according to CCR5 genotypes
Ancestral origin
The ancestral origin of CBUs' donors was analysed to test if there was a relationship between it and the CCR5 genotype.
Taking into account the samples with known ancestral origin, 92.40% of cord blood donors had a European ancestry, 4.33% had a South-American ancestry, 2.55% were African and 0.71% was from other less represented groups (Table 1) . When the distribution of ancestral origin was studied according each CCR5 genotype (Table 1) , a significant association was found between this variable and the presence of the deletion (P < 0.001). In spite the statistical test cannot define which ancestry has the association, we found that the percentage of samples that had a European ancestry was higher when the CCR5-Δ32 mutation was present. The percentage of European units that had the CCR5-Δ32 deletion was 14.77%, while the percentage of deleted units for the South-American, African and for the other less represented ancestral origins was 8.39, 1.82 and 6.52% respectively, indicating an increased likelihood for the mutation in the European ancestry.
Gender and blood type
The number and the percentage of samples of each blood type and gender were calculated (Table 1) . Besides, it was studied whether the distribution of different blood types and gender of the donors were different among the three CCR5 groups (Table 1) . O positive and A positive groups were the commonest blood types in the three groups. As expected, there was not a significant association between CCR5 genotype and blood type (P = 0.308). Neither it was found a significant association between CCR5 genotype and gender of the donors (P = 0.234), which was approximately 50% female and 50% male in each case.
HLA frequencies
Antigenic frequencies of HLA genes were calculated for each CCR5 group (Fig. 2) and were analysed to test if there was a correlation between the deletion and HLA types. There was not found any significant association among the antigens studied for the HLA-A, HLA-B and HLA-DRB1 genes and the CCR5 genotype (P = 0.627, P = 0.834, P = 0.849 respectively). In addition, we calculated the most frequent haplotypes in the HM group. The A*29:02, B*44:03, DRB1*07:01 was the most represented one, which appeared in 15 (5.51%) of all the HM CBUs ( Table 2 ).
Discussion
After CCR5 genotyping of 20,236 CBU selected for their cell quality from REDMO, we found a total of 130 CCR5-Δ32/Δ32 CBUs, which represents a percentage of 0.64%. These results were comparable to those obtained by Petz and colleagues, who genotyped approximately 25,000 CBUs from the inventories of StemCyte International Cord Blood Centre and other collaborating CBBs to produce a repository of CCR5-Δ32/Δ32 CBUs [18] . Accordingly, the allele frequency was 7.18%, close to other reported ranging from 6.5% to 12.8% in European population [3] [4] [5] , as expected because most CBUs analysed had a Caucasian origin. Our series were in the lower range probably because of the southern European origin of most of our donors.
To evaluate cell quality of the CCR5-Δ32/Δ32 CBUs, TNC and CD34 + content of the three CCR5 groups was analysed. Interestingly, significant differences were found WT   01  02  03  11  23  24  25  26  29  30  31  32  33  34  36  66  68  69  74  80   07   01  03  04  07  08  09  10  11  12  13  14  15  16   08  13  14  15  18  17  35  37  38  39  40  41  42  44  45  47  48  49  50  51  52  53  55  56  57  58  67 showing a lower cell amount in CCR5-Δ32 homozygotes CBUs. This unexpected data has never been reported and the impact in transplantation setting is uncertain. Chemokines and chemokines receptors play key roles in the trafficking, recruitment and activation of immune cells. CCR5 is expressed on antigen-presenting cells and immune effector cells, and it has also been reported its expression on peripheral blood-derived CD34 + hematopoietic progenitor cells [19, 20] , suggesting its importance on the function of these cell types. In previous studies, some authors have published data suggesting the role of CCR5 ligands in the function of the hematopoietic system. In particular, the capacity of MIP-1 alpha, a CCR5 ligand, to modulate cytokine-induced proliferation of stem cells [21] [22] [23] or even its protecting role of stem cell in expansion cultures [24] was reported. Lack of MIP-1 alpha signalling in CCR5-Δ32/Δ32 subjects may interfere in this process and may explain some of our findings. Nevertheless, these studies are very limited to support that the CCR5-Δ32/Δ32 units could have reduced engraftment potential and, consequently, further studies are necessary to understand the impact of this finding. Even though people having the CCR5-Δ32/Δ32 genotype appear to be healthy, probably because of the redundancy in the chemokines system, there are reports where the CCR5-Δ32 polymorphism has been studied for its possible implication in some immunologically mediated diseases [25] [26] [27] . However, some of these studies present discrepancies, possibly due to genetic background differences between the populations studied, and no conclusive results exist regarding the lack of CCR5 expression and its implication in the immune function.
On the other hand, we analysed different CBUs' characteristics according to CCR5 genotypes. Regarding ancestral origin, we found a statistical significant association with the CCR5 genotype. Despite the higher percentage of CCR5-Δ32 CBUs in the European ancestry, it is important to consider that nearly 40% of the samples studied have an unknown origin, which may interfere in the result. Blood type and gender were also analysed to test whether these variables are associated to CCR5 genotyping but we did not find an association.
In addition, due to HLA genes are associated with autoimmune diseases, infectious diseases and a resistance or susceptibility to HIV [28] it was analysed whether a significant association among some HLA polymorphisms and the presence of the CCR5-Δ32 deletion exists. No specific HLA association was found, as expected because of the different chromosome localization of the CCR5 and HLA genes. In our study, we have also inferred the most frequent haplotypes in the CCR5-Δ32/Δ32 group and found similar frequencies between those from the Spanish population. In particular, the most frequent haplotype in CCR5-Δ32/Δ32 CBUs was the most frequent in Spain [29] .
Considering the estimates of Gonzalez and colleagues [5] and the worldwide availability of 700,000 cryopreserved CBUs, it is expected that 3500-7000 units of them will be CCR5-Δ32/Δ32. According to the results observed after allo-HCT using CCR5-Δ32/Δ32 CBUs to cure HIV infected patients, it may be convenient to continue enlarging the CCR5 genotyping [18] . This would ensure a more reliable access to the therapy for HIV patients suffering from severe hematopoietic disorders requiring stem cell transplantation. Moreover, to increase the information available for each cryopreserved CBU, we think it should be considered to include the CCR5 genotyping together with the HLA genotyping in CBB typing policy. In this direction, next generation sequencing technology may help to accelerate the typing of large inventories worldwide and due to its high yield and low cost, allows us to consider it for CBUs, bone marrow and peripheral blood donor's CCR5 genotyping.
In summary, the development of CCR5-Δ32 CBU inventories is feasible and should be included in the typing policy of public CBBs to improve the offer of an appropriate donor to eligible patients. In addition, we hope this study will encourage other CBBs to perform an extended CCR5 genotyping of their best-quality cryopreserved CBUs in order to enlarge the CCR5-Δ32 CBU inventory. On the other hand, lower cell counts have been found in the CCR5-Δ32 homozygous CBUs. Further studies are required to understand the impact of this finding to know if the hematopoietic potency of these units is maintained and, consequently, whether their expected clinical outcomes are achieved. 
